Search results
Added:
5 years ago
Dr Paolo Colonna (Cardiology Department, Policlinico of Bari Hospital, Bari, IT) discusses the EMIT AF/VTE study, which investigates if periprocedural edoxaban management in routine clinical practice is associated with lower bleeding risk.
Filmed on site at EHRA 2019 by Radcliffe Cardiology.
Questions:
1. What is the aim of this study?
2. What is the design of the registry and edoxaban dosing…
View more
Added:
1 year ago
BCIS ACI 2023 – Dr Ziad Ali (St Francis Hospital & Heart Center, Roslyn, NY, US) summarises his ACI keynote lecture on intracoronary imaging in acute coronary syndromes. Dr Ali briefly discusses the FLAVOUR trial demonstrated that in patients with with intermediate coronary stenosis, FFR-guided PCI is noninferior to IVUS-guided PCI.
Recorded on-site BCIS ACI 2023, London.
View more
Added:
2 years ago
In this insightful discussion, Dr Aloke V Finn (CVPath Institute & University of Maryland, Baltimore, MD, US) and Dr Farshad Forouzandeh (Case Western Reserve University Cleveland, Cleveland, OH, US) discuss key questions relating to vulnerable plaque in patients with acute coronary syndrome:
How has intravascular imaging improved our understanding of vulnerable plaques, and in which direction…
View more
Added:
1 year ago
HRX 22 - In this short video, Chief Business Owner of Anumana Inc, David McMullin (Anumana, Inc., Cambridge, MA, US) joins us to discuss their FDA-Approved ECG-AI technology and the implementations this could have in daily practice.
To learn more about this technology, click here.
Questions:
1. Please outline Anumana's FDA-approved ECG-AI, and the clinical uses this could have in daily practice…
View more
Added:
3 years ago
Dr Rodrigo Estévez-Loureiro (University Hospital Alvaro Cunqueiro, Vigo, SP) discusses the outcomes of MitraClip in patients with acute mitral regurgitation in AMI with and without cardiogenic shock.
Questions
1. What is the background of the study?
2. How did you define cardiogenic shock?
3. What was the design, patient population and endpoints?
4. What were the key results?
5. What…
View more
Added:
1 year ago
In this short and engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most anticipated trials of EuroPCR 2022.
Which late-breaking science trials could have the most impact on practice? What are the considerations and challenges? What are the latest advances in interventional cardiology?
…
View more
Added:
2 years ago
In this short interview from our coverage of the ACC.22 late-breaking trials, Dr Pim van der Harst and Dr Marie-Sophie de Koning (University Medical Center Groningen, NL) discuss the data from the GIPS-IV trial which investigates the safety and efficacy of the hydrogen sulfide (H2S) donor sodium thiosulfate (STS) in patients presenting with ST-segment elevation myocardial infarction (STEMI) …
View more
Added:
1 year ago
ACC.23/WCC - Principal investigator, Dr Joo-Yong Hahn (Samsung Medical Center, KR) joins us to discuss the findings of the RENOVATE-COMPLEX-PCI late-breaking trial (Samsung Medical Center). The investigators compared clinical outcomes between intravascular imaging guided (IVUS) versus angiography guided (OCT) percutaneous coronary intervention (PCI) in 1639 patients with complex lesions …
View more
Added:
1 year ago
ESC Congress 2022 — In this short and practice-focused review, Dr Martha Gulati, Associate Director of the Barbra Streisand Women Heart Center and Director of CVD Prevention(Cedars-Sinai Medical Center, US) shares some her thoughts on the top 3 hot line trials.
Trials covered in detail include:
00:27: TIME:The Treatment in Morning versus Evening
01:57: SECURE:A polypill strategy in secondary…
View more
Added:
1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principle investigator, Dr Divaka Perera (King’s College London & Guy’s & St Thomas’ Hospital, UK) and investigator, Dr Peter O'Kane (Royal Bournemouth Hospital, UK) to discuss the REVIVED-BCIS2 viability analysis (NCT01920048).
This analysis of the REVIVED-BICS2 trial found that viability…
View more
« First